These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23904140)

  • 21. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
    Delaney WE; Yang H; Miller MD; Gibbs CS; Xiong S
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3702-10. PubMed ID: 15388423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding synergy.
    Geary N
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(3):E237-53. PubMed ID: 23211518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The statistics of synergism.
    Slinker BK
    J Mol Cell Cardiol; 1998 Apr; 30(4):723-31. PubMed ID: 9602421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A New Bliss Independence Model to Analyze Drug Combination Data.
    Zhao W; Sachsenmeier K; Zhang L; Sult E; Hollingsworth RE; Yang H
    J Biomol Screen; 2014 Jun; 19(5):817-21. PubMed ID: 24492921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additivity of inhibitory effects in multidrug combinations.
    Russ D; Kishony R
    Nat Microbiol; 2018 Dec; 3(12):1339-1345. PubMed ID: 30323252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study.
    Sperrin M; Thygesen H; Su TL; Harbron C; Whitehead A
    Pharm Stat; 2015; 14(3):216-25. PubMed ID: 25810342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pharmacodynamic model of clinical synergy in multiple myeloma.
    Sudalagunta P; Silva MC; Canevarolo RR; Alugubelli RR; DeAvila G; Tungesvik A; Perez L; Gatenby R; Gillies R; Baz R; Meads MB; Shain KH; Silva AS
    EBioMedicine; 2020 Apr; 54():102716. PubMed ID: 32268267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis.
    Hope WW; Warn PA; Sharp A; Reed P; Keevil B; Louie A; Denning DW; Drusano GL
    J Infect Dis; 2005 Aug; 192(4):673-80. PubMed ID: 16028137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.
    Cichewicz DL; McCarthy EA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1010-5. PubMed ID: 12604676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.
    Kashif M; Andersson C; Åberg M; Nygren P; Sjöblom T; Hammerling U; Larsson R; Gustafsson MG
    Mol Cancer Ther; 2014 Jul; 13(7):1964-76. PubMed ID: 24755197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maternal and neonatal herpes simplex virus infections.
    Keller DL
    N Engl J Med; 2009 Dec; 361(27):2678-9; author reply 2679. PubMed ID: 20050389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.